British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...

Urgent need for standardization in dental education and clinical practices: Dr Ashok Dhoble: Shardul Nautiyal, Mumbai Monday, August 11, 2025, 08:00 Hrs [IST] Dr Ashok Dhoble, sec ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

As of 0715 GMT, the blue-chip index FTSE 100 gained 0.3% and the British pound rose 0.09% against the dollar to above 1.34.

More than 600,000 cases of gonorrhoea were reported in the U.S. in 2023, according to the U.S. Centers for Disease Control and Prevention. There are no vaccine licenses in the U.S. for preventing the ...

Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.

British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral ...

(Alliance News) - GSK PLC on Monday said its gepotidacin drug has been accepted for priority review in the US as an oral option for the treatment of a form of sexually transmitted infection gonorrhoea ...

(Alliance News) - Plus500 announced USD165.0 million of new shareholder returns, while Marshalls maintained its profit outlook, anticipating "no improvement in market activity levels" in the remainder ...